Please assess the completion status of the following clinical trial:

Trial Title: Mandibular Furcation II Regeneration

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Subject must be ≥ 20 years~* Subject must have periodontal disease as determined by the World Workshop 2017 criteria~* Subjects must be undergoing periodontal treatment or follow-up and present 1 or more pair of bilateral mandibular molars affected by furcation involvement grade II with PPD \>4 mm, and the furcation fornix must be below a tangential line from the distal to mesial interproximal crestal bone level~* Competent to give consent~Exclusion Criteria:~The following must not be present at the time of enrolment;~* Previous radiotherapy to the jaws, current use of chemotherapy, systemic long-term corticosteroid treatment~* Present or past use of bisphosphonate treatment~* Pregnant or nursing subjects~* Patients classified as \> class 2 according to the ASA (American Society of Anesthesiologists) physical status classification~* Previous surgical therapy of included furcation defects~* Inability to comprehend and respond to the quality of life questionnaire~* Dental restorations or prosthesis involving the furcation area~* Root fractures or suspected infractions~* Caries lesions in the furcation area~* No systemic antibiotic treatment within 3 months prior to intervention

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Regenerative therapy w/BCP and collagen membrane (Type: EXPERIMENTAL): In this arm, treatment of furcation grade II defects includes open flap debridement and regenerative therapy with biphasic calcium phosphate (BCP) and collagen membrane.
- Regenerative therapy w/BCP and enamel matrix proteins (Type: ACTIVE_COMPARATOR): In this arm, treatment of furcation grade II defects includes open flap debridement and regenerative therapy with biphasic calcium phosphate (BCP) and enamel matrix proteins.

Based on this trial design, predict the completion outcome and termination type (if applicable).